MedPath

The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Combination Product: The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia
Registration Number
NCT05623228
Lead Sponsor
Rakitzi, Stavroula
Brief Summary

The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia.

Is it effective and efficacious?

Detailed Description

Individuals with schizophrenia and treatment resistant schizophrenia will participate on a group cognitive behavioral therapy and rehabilitation, in which Integrated Psychological Therapy and Metacognitive Training are going to be implemented. The therapy will last 60 biweekly sessions. This is a non randomized trial.

Speed of processing, working memory, verbal memory, visual memory, reasoning and problem solving, social cognition, symptoms, functional outcome and recovery will be evaluated before, after therapy and in a 6 months follow up.

MCCB, Social Perception Scale, the Greek Test for verbal memory, PANSS, WHO DAS 2. 0 (Greek), PSYRAT and the Recovery Assessment Scale will be used ih this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Diagnosis of schizophrenia
  • No relapse and hospitalization
  • Ambulant psychiatric treatment
Exclusion Criteria
  • Other psychotic disorders
  • Relapse and hospitalization
  • Substance abuse

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Therapy Group BThe combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniaTherapy Group B Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 2 individuals with schizophrenia
Therapy Group CThe combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniaTherapy Group C Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 8
Therapy Group FThe combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniaTherapy Group F Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3
Therapy Group AThe combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniaTherapy Group A Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 5 individuals with schizophrenia
Therapy Group GThe combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniaTherapy Group G Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented 3
Therapy Group DThe combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniaTherapy Group D Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 8
Therapy Group EThe combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniaTherapy Group E Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3
Therapy Group HThe combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophreniaTherapy Group H Intervention: Pharmacotherapy in combination with the Integrated Psychological Therapy and Metacognitive Training will be implemented. 3
Primary Outcome Measures
NameTimeMethod
Symptoms, PANSS Greek VersionBaseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks)

(PANSS) Greek Version Positive symptoms (minimum 8 maximum 49) low scores better outcomes Negative symptoms: (minimum 8 maximum 49) low scores better outcomes General Psychopathology: (minimum 17 maximum 112) low scores better outcomes Total: Sum of positive, negative and general symptoms (minimum 31, maximum 210), low scores better outcomes The total score is used in the statistical analysis

(PSYRAT)

Auditory hallucinations (minimum 0 maximum 44) low scores better Delusion (minimum 0 maximum 24) low scores better Data is analyzed with SPSS 13

Functional OutcomeBaseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks)

WHO DAS 2.0 WHODAS total: (functional outcome) (minimum 0-maximum 100) low scores better outcomes Data are analyzed with SPSS 13

RecoveryBaseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks)

RAS-DS scale Total score (sum of the scores) (0-152) high scores are better outcomes

Data is analyzed through SPSS 13

Cognitive Functions: Matrics Consensus Cognitive Battery (MCCB), Greek Verbal TestBaseline T1 (preintervention)-follow-up T3 (after 6 months, up to 55 weeks)

Greek verbal memory test: (verbal memory semantic condition (average) (minimum 0-maximum 40) (high scores better outcomes) MCCB: (Neuropsychological Assessment Battery) (NAB) (reasoning and problem solving): (minimum 0 maximum 26) (high scores better outcomes) Data is analyzed through SPS 13.

Secondary Outcome Measures
NameTimeMethod
Intelligent QuotientBaseline T1 (preintervention)

Intelligence, high scores are better Data is analyzed through SPSS 13.

Trial Locations

Locations (1)

Stavroula Rakitzi

🇬🇷

Athens, Greece

© Copyright 2025. All Rights Reserved by MedPath